Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lundbeck and Proximagen Group have signed an agreement to jointly apply their expertise in CNS drug development towards achieving their collective strategic and growth objectives.
Subscribe to our email newsletter
Under the deal, both the firms will focus on developing three of Proximagen’s programmes, with the aim of identifying novel innovative therapies for serious diseases such as epilepsy, pain and inflammatory disorders.
Lundbeck will also receive certain negotiation rights in relation to these programmes.
Proximagen CEO Kenneth Mulvany said the partnership with Lundbeck validates their strategy and represents a major step forward in realizing the value of key compounds in their pipeline.
"We look forward to working closely with Lundbeck as we each share our expertise to develop therapies for patients," Mulvany said.